Cannabinoid Drug For Agitation In Alzheimer’s Yields Cognitive Improvements In Clinical Trial
IGC Pharma, Inc.(NYSE:IGC) reported additional interim data from its ongoing Phase 2 clinical trial evaluating IGC-AD1 for agitation in dementia associated with Alzheimer’s disease. IGC-AD1 targets neuro-inflammation and CB1 receptor dysfunction,. The investigational drug contains THC as one of two active pharmaceutical agents.
Interim data analysis reveals cognitive improvements in the active treatment group versus the placebo group, marking a meaningful step toward developing a therapy that may influence underlying disease progression.
These findings align with previously announced preclinical data, which showed a reduction in amyloid plaque aggregation by approximately 20% and improved spatial memory by about 50% in Alzheimer’s cell lines and mouse models, respectively.
“The cognitive improvements observed in our interim results align with preclinical evidence of IGC-AD1’s active pharmaceutical ingredients’ impact on amyloid plaques and spatial memory,” stated Ram Mukunda, CEO of IGC Pharma. “While agitation remains the primary focus of the Phase 2 trial, these exploratory findings strengthen our confidence in IGC-AD1’s potential …